Company Creation
There are opportunities for investment, partnership and leadership roles with the new companies we create each year.
Our Company Creation supports and facilitates the creation of high-tech, innovative companies. We identify and "spin out" commercial and not-for-profit activities from our world class research.
You might be interested in investing or partnering with one of our companies. Or you might want to join as an experienced executive who can support a company's growth. If you are an investor, an advisor or an academic and are interested in working with us and our portfolio of companies, please get in touch.
Spin out companies
We have an excellent track record for producing spin-out companies from applied research and play a significant role in the development of new products and services.
Our Spin out companies also contribute to the development and vitality of the region through new jobs and revenue creation.

Executives into Business
To enable our deep tech and innovative spin-out companies to grow and maximise their success we ensure they are supported by a strong management team. This may involve recruiting executives with a high level of business acumen, and experience in scaling up businesses, to enable our spin outs to reach their full potential.
We offer renumeration and equity to attract ambitious, experienced, and well-networked business executives and management teams to early-stage ventures. To reflect the sectors in which we are currently developing spin outs we are particularly looking for executives with experience in deep tech life sciences and engineering.
If you believe you have the skills and experience to lead a spin-out business, or want to find out more, get in touch.
Northern Accelerator
We are founding members of the Northern Accelerator programme, a collaboration between the universities in the north-east of England. It is a programme that has accelerated the commercialisation of innovation to boost our region’s economy, making a real-world impact from world-leading research.
Advanced Electric Machines’ unique, low cost traction motor technology is designed to drive tomorrow's hybrid, range extended and electric commercial vehicles. The technology, designed specifically for commercial vehicles, delivers excellent performance in a robust package.
Aelius Biotech is a contract research company specialising in modelling the mucosal surfaces of the aerodigestive tract. Aelius' Integrated Model Gut System is a lab model stretching from the mouth to the large intestine which can be used to test drug delivery and absorption, screen formulations, develop and test functional foods and study pre- and pro- biotics.
Alcyomics is a UK based unique pre-clinical service provider using Skimune®, non-artificial human skin explants for safety and efficacy assessment of novel compounds and drugs. Their mission is to provide novel solutions for pre-clinical drug safety and efficacy testing for therapeutics including cellular therapies and to extend its technologies for use in the chemical and cosmetic industries.
Armatus Oceanic is deep-sea venture focused on making the deep sea accessible to all. Their continuing mission is to develop and deploy underwater technology to allow the exploration and surveying of up to 11,000 meters below the ocean’s surface.
AMLo Biosciences is dedicated to providing a prognostic test for early AJCC Stage I and Stage II melanoma to better identify a patient’s true risk of disease progression. They have identified two proteins (AMBLor®) in the skin overlying the primary tumour that are lost in high-risk melanoma.
Atelerix offers a transformative hydrogel technology for the storage and transport of viable cells including stem cells and cell-based assays at ambient temperatures. This overcomes the barriers presented by the current need for cryo-shipping as it is simple, cell-friendly and offers immediate access to stem cell therapies.
Apix Nutrition has developed a proprietary range of novel feeds for honeybees that will deliver a balanced and healthy diet in pre-pack and ready-to-eat formats. Their aim is to address a failure in the market for effective bee nutrition throughout the world.
https://apixnutrition.com
3D Biotissues (VEO) transplantable corneas using 3D bio-printing. They are a leading provider of cutting-edge technologies in corneal 3D printing. Founded by Professor Che Connon at Newcastle University, using knowledge of corneal biology gained after 20 years of performing cutting edge research into a fundamental understanding of how the cornea works.
CellRev’s mission is to be the leader in continuous cell culturing technologies, providing our clients with highly sophisticated and innovative products. They have expertise in the design and bioactivity testing of peptide-based molecules for biotechnological applications. CellRev has also developed a smart coating, demonstrating the concept of continuous cell manufacture.
Changing Health provides digital services aimed at people suffering from, or at risk of, Type 2 diabetes. They provide access to a range of digital health education articles and interactive activities on diet and exercise along with personal telephone access to a specialist lifestyle behaviour change coach.
Demuris is a drug discovery and development company employing state-of-the-art platform technologies in natural product discovery, design and production. The starting point for Demuris’ portfolio of new drug development often lies in a unique collection of Actinomycete bacteria. These organisms can manipulate the behaviour of surrounding organisms, including bacteria, fungi, plants and animals.
Dragonfly Insulation Ltd has been established to scale up aerogel manufacture based on the innovative and simplified manufacturing process with low energy consumption to offer various forms of aerogel products.
Electrokinetic specialises in provision of slope stabilisation and ground strengthening products and services, employing electrokinetic technologies, principally for the infrastructure and waste reduction markets.
ESP Diagnostics Ltd (ESPDx) has developed a simple and accurate test for early-stage diagnosis and early pre-symptomatic detection of both dementia with Lewy Bodies and Parkinson's disease. The test measures biomarkers in extracellular vesicles enabling early and accurate and diagnosis of neurodegenerative disorders for patients, clinicians, healthcare providers, and drug developers.
e-Therapeutics plc accelerates drug discovery through a novel view of disease networks. By combining biological expertise and a powerful computer-based platform, they create and analyse network models of disease to identify likely proteins that could effectively be disrupted to treat the disease.
FibroFind has combined decades of research experience with robust preclinical drug development testbeds to provide world-class research solutions in liver, kidney and lung disease.
Future Homes Alliance ambition is to develop housing that caters to the needs and aspirations of present and future generations. Inspired by Newcastle City Futures and Newcastle’s commitment to becoming an Age Friendly City, this partnership sets out to challenge current ideas about housing. The project offers residents the opportunity to live, work, learn and play in an attractive urban setting. Developing dwellings that offer a model of living to be replicated on a regional and ultimately national scale.
GlycoScore is a patented blood test that detects a panel of novel biomarkers and can accurately diagnose prostate cancer. The GlycoScore analytes are detected using a simple method called ELISA making the test easily adoptable by pathology labs worldwide with no additional capital investment needed.
Indicatrix offer a unique under-oil micro-crystallisation technique for the crystallisation of organic soluble small molecules, to enable solid state molecular structural analysis in the pharmaceutical and chemical industries. Indicatrix perform many thousands of individual experiments with only a few milligrams of analyte, allowing them to solve the most challenging of industrial small molecule crystallisation problems.
Microbritt is a rapid micro-manufacturing company, akin to 3D printing services, for the manufacturing of novel complex microscale products from brittle materials, like silicon. They allow customers to make products which cannot be manufactured using conventional technology, plus make them faster.
Newcells Biotech’s expertise is in the production of induced pluripotent stem cells and their differentiation into a wide range of reliable and reproducible cell and tissue types. They provide customers engaged in drug discovery, pre-clinical development and disease mechanism investigation, with the best quality cells and services.
NunaBio is a biotech company that invent, design, and engineer new technologies and products for chemical and biological applications. Their focuses include biosensing across multiple industries and platforms, and DNA/gene production for use in cell and gene therapies, vaccines, and diagnostics.
Scubatx develops technology to preserve organs. In doing so they offer healthcare providers significant net savings, and so help clinicians around the world to increase the pool of life-giving organs.
Skin Life Analytics has developed a non-invasive test that can reveal if somebody’s skin is at risk of ageing prematurely from lifestyle risks such as exposure to sunlight and poor sleep which can damage skin cells. In addition to a skin swab, the test includes a lifestyle assessment that can suggest changes to improve skin condition. They also utilise face scan technology to pinpoint areas that would benefit from a targeted care regime.
TREAT-NMD is a network for the neuromuscular field that provides an infrastructure to ensure that the most promising new therapies reach patients as quickly as possible. Their focus is to develop tools that industry, clinicians and scientists need to bring novel therapeutic approaches through preclinical development and into the clinic.
XR Therapeutics (XRT) provide a step-change in the way therapeutic interventions for anxiety are delivered to people with autism, phobias and situation-specific anxieties. Through the commercialisation of over 9 years of research, they have developed a product which combines traditional CBT and exposure therapies through a wide range of virtual reality environments.
https//xrtherapeutics.co.uk
Our Team
We have extensive, hands-on experience of creating and successfully managing new businesses.
The team consists of Rick McCordall, Head of Company Creation, Lizzie Withington, Company Creation Manager and David Huntley, Company Creation Commercial Advisor. If you would like to discuss any business opportunities with the team please contact Jill Moffat, our Project Support Officer/PA.